Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre …
…, M Tongo, E Mpoudi-Ngolé, A Montoyo, N Mercier… - The lancet HIV, 2020 - thelancet.com
Background Updated WHO guidelines recommend a dolutegravir-based regimen as the
preferred first-line treatment for HIV infection and low-dose efavirenz (400 mg) as an alternative. …
preferred first-line treatment for HIV infection and low-dose efavirenz (400 mg) as an alternative. …
[HTML][HTML] An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients …
…, C Delmas, J Saillard, A Dechanet, N Mercier… - Clinical Microbiology …, 2021 - Elsevier
Objectives We evaluated the clinical, virological and safety outcomes of lopinavir/ritonavir,
lopinavir/ritonavir–interferon (IFN)-β-1a, hydroxychloroquine or remdesivir in comparison to …
lopinavir/ritonavir–interferon (IFN)-β-1a, hydroxychloroquine or remdesivir in comparison to …
[HTML][HTML] Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives
…, A Diallo, S Le Mestre, N Mercier… - Clinical Microbiology …, 2021 - Elsevier
Objectives Molecular assays on nasopharyngeal swabs remain the cornerstone of COVID-19
diagnostics. The high technicalities of nasopharyngeal sampling and molecular assays, as …
diagnostics. The high technicalities of nasopharyngeal sampling and molecular assays, as …
Smell training improves olfactory function and alters brain structure
S Al Aïn, D Poupon, S Hétu, N Mercier, J Steffener… - Neuroimage, 2019 - Elsevier
Training and repeated exposure to odorants leads to enhanced olfactory sensitivity. So far,
the efficacy of intensive olfactory training on olfactory function in a healthy population and its …
the efficacy of intensive olfactory training on olfactory function in a healthy population and its …
[HTML][HTML] RNase III CLASH in MRSA uncovers sRNA regulatory networks coupling metabolism to toxin expression
…, I Ivanova, P Arede, RL Zapf, N Mercier… - Nature …, 2022 - nature.com
Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterial pathogen responsible for
significant human morbidity and mortality. Post-transcriptional regulation by small RNAs (…
significant human morbidity and mortality. Post-transcriptional regulation by small RNAs (…
Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: A phase 1b, double-blind, randomised, placebo-controlled dose-escalation …
…, AS Debrie, D Raze, L Coutte, N Mercier - The Lancet Infectious …, 2020 - thelancet.com
Background Long-term protection and herd immunity induced by existing pertussis vaccines
are imperfect, and a need therefore exists to develop new pertussis vaccines. This study …
are imperfect, and a need therefore exists to develop new pertussis vaccines. This study …
Chronic use of renin‐angiotensin‐aldosterone system blockers and mortality in COVID‐19: A multicenter prospective cohort and literature review
…, A Diallo, S Le Mestre, N Mercier… - Fundamental & …, 2021 - Wiley Online Library
Aims The role of renin‐angiotensin‐aldosterone system (RAAS) blockers on the course of
coronavirus disease 2019 (COVID‐19) is debated. We assessed the association between …
coronavirus disease 2019 (COVID‐19) is debated. We assessed the association between …
Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19
…, J Mayaux, A Mekontso-Dessap, N Mercier… - The Lancet Infectious …, 2022 - thelancet.com
We reported the preliminary results of the DisCoVeRy trial regarding the efficacy and safety
of remdesivir in hospitalised patients with COVID-19 in February, 2022. 1 Remdesivir did not …
of remdesivir in hospitalised patients with COVID-19 in February, 2022. 1 Remdesivir did not …
Cardiac Adverse Events and Remdesivir in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19): A Post Hoc Safety Analysis of the Randomized …
…, N Peiffer-Smadja, N Mercier… - Clinical Infectious …, 2024 - academic.oup.com
Background We aimed to evaluate the cardiac adverse events (AEs) in hospitalized patients
with Coronavirus Disease 2019 (COVID-19) receiving remdesivir plus standard of care (SoC…
with Coronavirus Disease 2019 (COVID-19) receiving remdesivir plus standard of care (SoC…
[HTML][HTML] Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open …
…, R Landman, AG Marcelain, S Matheron, N Mercier… - The Lancet …, 2024 - thelancet.com
Background Due to the low number of individuals with HIV-2, no randomised trials of HIV-2
treatment have ever been done. We hypothesised that a non-comparative study describing …
treatment have ever been done. We hypothesised that a non-comparative study describing …
